摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-methanesulfonyl-2-methylpentane

中文名称
——
中文别名
——
英文名称
3-methanesulfonyl-2-methylpentane
英文别名
2-Methylpentan-3-yl methanesulfonate;2-methylpentan-3-yl methanesulfonate
3-methanesulfonyl-2-methylpentane化学式
CAS
——
化学式
C7H16O3S
mdl
——
分子量
180.268
InChiKey
BDPMPTNYGUEZDV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    11
  • 可旋转键数:
    4
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    51.8
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    3-methanesulfonyl-2-methylpentane3-(2,4-dichlorophenyl)-8-ethyl-1-methyl-1,2,3,7-tetrahydro-6H-purin-6-onepotassium carbonate 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 4.0h, 以22%的产率得到3-(2,4-Dichloro-phenyl)-8-ethyl-7-(1-ethyl-2-methyl-propyl)-1-methyl-1,2,3,7-tetrahydro-purin-6-one
    参考文献:
    名称:
    Design, Synthesis, and Biological Evaluation of 1,2,3,7-Tetrahydro-6H-purin-6-one and 3,7-Dihydro-1H-purine-2,6-dione Derivatives as Corticotropin-Releasing Factor1 Receptor Antagonists
    摘要:
    A growing body of evidence suggests that CRF1, receptor antagonism offers considerable therapeutic potential in the treatment of diseases resulting from elevated levels of CRF, such as anxiety and depression. A series of novel 1,2,3,7-tetrahydro-6H-purin-6-one and 3,7-dihydro-1H-purine-2,6-dione derivatives was synthesized and evaluated as corticotropin releasing factor-1 (CRF1) receptor antagonists. Compounds within this series, represented by compound 12d (IC50 = 5.4 nM), were found to be highly potent CRF, receptor antagonists. In addition, compounds 12d and 12j were determined to be selective CRF, antagonists. The synthesis, structure-activity relationships and pharmacokinetic properties of compounds within this series is presented.
    DOI:
    10.1021/jm049787k
点击查看最新优质反应信息

文献信息

  • ELECTROLYTIC SOLUTION FOR NONAQUEOUS ELECTROLYTIC SOLUTION SECONDARY BATTERIES AND NONAQUEOUS ELECTROLYTIC SOLUTION SECONDARY BATTERY
    申请人:Central Glass Co., Ltd.
    公开号:EP3333962B1
    公开(公告)日:2020-10-07
  • Design, Synthesis, and Biological Evaluation of 1,2,3,7-Tetrahydro-6<i>H</i>-purin-6-one and 3,7-Dihydro-1<i>H</i>-purine-2,6-dione Derivatives as Corticotropin-Releasing Factor<sub>1</sub> Receptor Antagonists
    作者:Richard A. Hartz、Kausik K. Nanda、Charles L. Ingalls、Vijay T. Ahuja、Thaddeus F. Molski、Ge Zhang、Harvey Wong、Yong Peng、Michelle Kelley、Nicholas J. Lodge、Robert Zaczek、Paul J. Gilligan、George L. Trainor
    DOI:10.1021/jm049787k
    日期:2004.9.1
    A growing body of evidence suggests that CRF1, receptor antagonism offers considerable therapeutic potential in the treatment of diseases resulting from elevated levels of CRF, such as anxiety and depression. A series of novel 1,2,3,7-tetrahydro-6H-purin-6-one and 3,7-dihydro-1H-purine-2,6-dione derivatives was synthesized and evaluated as corticotropin releasing factor-1 (CRF1) receptor antagonists. Compounds within this series, represented by compound 12d (IC50 = 5.4 nM), were found to be highly potent CRF, receptor antagonists. In addition, compounds 12d and 12j were determined to be selective CRF, antagonists. The synthesis, structure-activity relationships and pharmacokinetic properties of compounds within this series is presented.
查看更多